Comparison · NCT04847232-2c1a27a9
SZC (Active) vs Placebo: Incidence of the Composite of Cardiac Event Outcomes
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. SZC (Active) vs Placebo: Incidence of the Composite of Cardiac Event Outcomes. Trial comparisons, record NCT04847232-2c1a27a9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04847232-2c1a27a9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0882 | 0.0742 | 0.105 | wilson | |
| Risk in group 2 | 0.0887 | 0.0747 | 0.105 | wilson | |
| Risk difference, group 1 minus group 2 | -0.000526 | -0.0221 | 0.021 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.994 | 0.78 | 1.27 | log | |
| Odds ratio, group 1 over group 2 | 0.993 | 0.761 | 1.3 | log | |
| Number needed to treat, for one fewer participant with the outcome on SZC (Active) than on Placebo | 1,900 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | SZC (Active) | 5 g SZC QD to 15 g SZC QD | 119 | 1,349 | OG000 |
| Group 2 | Placebo | SZC Placebo | 119 | 1,341 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Incidence of the Composite of Cardiac Event Outcomes
- Description
Incidence of the composite endpoint of SCD, all stroke, or hospitalization/intervention/emergency department (ED) visit due to arrhythmias is analyzed based on Cox regression model with treatment and region as covariates. Patients with no events are censored at final clinical assessment, death, or disposition event.
- Time frame
- From Randomization (Visit 4) up to week 129 (Randomized Study Intervention Phase)
- Population
- Full analysis set.
Source ClinicalTrials.gov
Trial
- Title
- Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
- NCT number
- NCT04847232
- Phases
- PHASE3
- Conditions
- Hyperkalemia
- Interventions
- Sodium Zirconium Cyclosilicate (SZC), SZC Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2025-06-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04847232?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04847232-2c1a27a9